I
L-33 is a recently identified member of the family of IL-1-like cytokines that binds to the IL-33 receptor, formerly known as the orphan receptor ST2 of the IL-1 receptor family (1) . Like IL-18 and IL-1␤, the closely related IL-33 is synthesized as a 31-kDa precursor that can be processed to the mature cytokine by caspase 1. Similarly to the precursor of IL-1␣, IL-33 can translocate to the nucleus (2) . Although these members of the IL-1 family are potent inducers of cytokine production, the profile induced by the respective molecules differs. IL-1 is an important proinflammatory cytokine of the innate arm of immunity and also promotes proliferation of thymocytes (Th0), thus playing a role in adaptive immunity as well. IL-18 induces proinflammatory cytokines; however, its major feature, in collaboration with IL-12, is the induction of IFN-␥. Thus, IL-18 skews Th0 cells toward Th1 differentiation. Little is yet known about proinflammatory properties of IL-33. However, treatment of mice with IL-33 results in an increase in IL-4, IL-5, and IL-13 production, which suppresses Th1 differentiation and favors Th2 differentiation (1) .
The structural and functional similarities of IL-1, IL-18, and IL-33 can be extended to their receptors. IL-1 signal transduction is initiated by binding of either form of IL-1 to IL-1 receptor type I (IL-1R␣-chain), which undergoes a conformational change allowing the IL-1 receptor accessory protein (IL-1RAcP) to recognize the ligated IL-1RI. IL-1RAcP does not recognize IL-1. Both transmembrane proteins form a heterodimer, which results in the close association of the cytosolic Toll-like IL-1R (TIR) homology domains (3) . IL-1RAcP is essential for IL-1 signaling (4) (5) (6) , and the TIR domains of both chains are required to facilitate signaling (7, 8) . Ligand-mediated heterodimerization with subsequent intracellular association of strongly homologous, but discrete, TIR domains is a typical feature of the IL-1 receptor subfamily of TIR-domain-containing receptors. In accordance, the IL-18 receptor complex consists of IL-18R␣-and ␤-chains, both of which carry a TIR domain (9, 10) . Similar mechanisms have been described for IL-1Rrp2, the receptor for IL-1F6, IL-1F8, and IL-1F9, which also associates with IL1RAcP (11, 12) . Although ST2 has been known as an orphan receptor in the IL-1 receptor family for many years (13, 14) , its ligand remained elusive until IL-33 was identified (1) . It has been proposed that the IL-33R␣-chain also requires a ␤-chain containing a TIR domain and that this may be a member of the IL-1 receptor family (15) .
Here we demonstrate by different means that IL-1RAcP represents the IL-33R␤-chain necessary for IL-33 to induce responses in T cells and mast cells. This finding shows that IL-1RAcP may resemble a common ␤-chain used by more than one ␣-chain of the IL-1 receptor family. a plasmid encoding fl mIL-33R␣-chain. In addition, D6/76 cells were transfected with a constant concentration of plasmid encoding fl mIL-1RAcP. In both situations, the response to IL-33 was enhanced approaching the IL-1 response with respect to IL-2 production (Fig. 1B Left) and NF-B activation (Fig. 2B  Right) . This finding suggests that low expression of the endogenous IL-33R␣-chain is limiting IL-33 responses in these T cell lines.
IL-1RAcP Is Required in Mast Cells to Allow IL-33-Stimulated Cytokine
Release. Freshly isolated and differentiated murine bone marrow-derived (BMD) mast cells express ST2 (IL-33R␣-chains) on their surface (data not shown). Stimulation with rmIL-33 enhanced the constitutive production of the proinflammatory cytokine IL-6 to an extent comparable to LPS (Fig. 3A) . IL-33 also stimulated rapid release of TNF␣ and IL-1␤, but did not affect the low constitutive release of IL-13 (Fig. 3B) . Pretreatment with the monoclonal antibody (mAb) 4C5, which neutralizes IL-1RAcP (19, 20) , resulted in a concentration-dependent reduction of the IL-33-induced cytokine production. If mast cells were stimulated with low concentrations of rmIL-33 (1-3 ng/ml), a complete inhibition of stimulated IL-6 production could be achieved (Fig. 3C ) (TNF␣ release was inhibited 27% at 25 g/ml or 12% at 50 g/ml mAb 4C5, respectively). (Fig. 2 A) . Cotransfection with ⌬C-AcP reduced IRAK-1 activation. This result demonstrates that IRAK-1 is activated by the IL-33R complex as previously described (1) and that this activation depends on the presence of the TIR domain in fl mIL-1RAcP.
The activation of NF-B is a central element of the signaling pathways activated by the IL-1 receptor family. Although D6/76 cells responded to IL-18 and TNF␣, they did not respond to IL-1 or IL-33 by activation of NF-B. Upon transfection with fl mIL-1RAcP, NF-B activation was restored to both cytokines with no effect on TNF␣ or IL-18 response. Preincubation with mAb 4C5 inhibited IL-1-and IL-33-stimulated NF-B activation, but did not affect IL-18-or TNF␣-stimulated activation of the transcription factor (Fig. 2B Left) . ⌬C-AcP was not able to restore IL-1 or IL-33 responsiveness with respect to NF-B activation in D6/76 cells (data not shown). Transfection of EL-4 cells with increasing amounts of the plasmid-encoding ⌬C-AcP resulted in a concentration-dependent reduction of NF-B activation after IL-33 stimulation, demonstrating that the truncated form of mIL-1RAcP behaved in a dominant-negative fashion (Fig. 2C) . Transfection of EL-4 cells with increasing amounts of the plasmid encoding fl mIL-33R␣-chain resulted in an increase in NF-B activation after IL-33 stimulation while leaving the IL-1 response unaffected (Fig. 2B Right) . This finding proves the specificity of the observed effect for IL-33 and that the endogenous expression level of mIL-33R␣-chain limited the response to its ligand. Preincubation of EL-4 or IL-1RAcP-transfected D6/76 cells with mAb 4C5 resulted in a reduction of IL-1␤-and IL-33-stimulated NF-B activation (Fig. 2D) . NF-B activation was nearly completely inhibited by 4C5 after stimulation with rhIL-1␤, whereas rmIL-33-stimulated activation was reduced to Ϸ50%. The isotype-matched control antibody had no effect on IL-1-or IL-33-stimulated NF-B activation ( In summary, these results demonstrate that key elements of the classical signaling pathway used by the IL-1 receptor family such as IRAK-1, NF-B, and JNK were specifically activated by IL-33 only in the presence of fl IL-1RAcP.
The Interaction of IL-33R␣-Chain and IL-RAcP Is Dependent on IL-33.
After binding of IL-1 to either IL-1RI or IL-1RII, IL-1 receptors and IL-1RAcP form heterodimeric receptor complexes on the cell surface (7). To clarify whether such a complex also forms between IL-1RAcP and IL-33R␣-chain, epitope-tagged versions of IL-1RAcP and IL-33R␣ were coexpressed in HEK293RI cells. After stimulation with rmIL-33, complexes were coimmunoprecipitated. IL-1RAcP was coprecipitable with IL-33R␣-chain, and vice versa (data not shown), only in the presence of rmIL-33, but not if the cells were incubated with rhIL-1␤ (Fig.  4A) . In some experiments, we observed a weak interaction in the absence of ligand, which is because of the strong protein expression in HEK293RI cells. This result demonstrates that the interaction of the membrane-inserted forms of IL-1RAcP and IL-33R␣-chain is specific for and dependent on IL-33.
It has been shown that soluble IL-1R and IL-1RAcP interact in the presence of IL-1 (21, 22) . Employing a soluble IL-33R␣:Fc fusion protein and an epitope-tagged soluble IL-1RAcP, we could demonstrate a specific interaction in solution in the presence of IL-33, which was stable enough to be immunoprecipitated (Fig. 4B ). This result extends our finding that IL1RAcP is the coreceptor for IL-33R␣-chain from the membrane-inserted forms to the soluble molecules. . Cells were transiently cotransfected with a plasmid encoding mIL-33R␣-chain and either empty vector (e.v.), plasmids encoding C-terminally truncated mIL-1RAcP(⌬C-AcP), fl mIL-1RAcP (Left) (1 g of plasmid for every 5 ϫ 10 6 cells), or increasing amounts of plasmid encoding fl mIL-1RAcP (Right). Cells were stimulated with 100 ng/ml rmIL-33 (black bars) or 100 pg/ml rhIL-1␤ (gray bars), and mIL-2 was measured by ELISA 18 h later. Data depicted are means Ϯ SD from one experiment (triplicates or quadruplicates) of a series of at least three similar ones with comparable results.
Discussion
The IL-33R␣-chain, formerly known as ST2/T1, is a member of the IL-1 receptor family of TIR-domain-containing receptors. IL-33R␣-chain possesses a TIR domain in its cytoplasmic moiety, which is required for signaling (23) . The IL-33R␣-chain interacts with IL-33, which results in the recruitment of signaling molecules also found in the IL-1RI complex (1) . This result demonstrates the close relationship of IL-33R and IL-1R complexes as suggested by the use of chimeric molecules (24) . Thus, it has been proposed that the IL-33R␣-chain also requires a ␤-chain containing a TIR domain and that this may be a member of the IL-1 receptor family (1, 15) .
The signaling IL-1 receptor complex consists of a heterodimer of IL-1RI that binds IL-1 and IL-1RAcP, which recognizes the ligated IL-1RI (4, 5, 18, 20) . The signaling IL-18 receptor complex also consists of a heterodimer in which the IL-18R␣-chain binds IL-18 (25) and the IL-18R␤-chain (26) functions as a coreceptor. Two additional heterodimeric receptor complexes in the IL-1R system have been described. IL-1F9 was reported to activate NF-B in an IL-1Rrp2-dependent manner (11) . This finding was extended by showing that three members of the IL-1 family of cytokines (IL-1F6, IL-1F8, and IL-F9) bind to IL1Rrp2 and induce signaling events practically identical to IL-1 (12) . IL-1F6, IL-1F8, and IL-1F9 were not able to induce signaling in mouse embryonic fibroblasts derived from IL1RAcP knockout animals. In addition, a neutralizing antibody against IL-1RAcP inhibited the response of cells to these ligands, strongly suggesting that IL-1RAcP could function as a coreceptor for ligated IL-1Rrp2 (12) . Independently, chimeric receptor molecules of the then-orphan receptor ST2 were generated to investigate the signaling pathways activated by its cytoplasmic TIR domain. In D6/76 cells, IL-1RAcP served as a coreceptor for the ST2-chimera; however, no activation of NF-B was detectable (27) .
Here we show that IL-33R␣ (ST2) requires IL-1RAcP to function as a signaling receptor for IL-33 in two different types of cells. We also show that central signaling pathways activated by IL-33 are comparable to IL-1. We detected NF-B activation by IL-33 and IL-1, which is in contrast to the data obtained in the chimeric model (27) , but in accordance with transiently transfected HEK293 cells (1) . This discrepancy may be because chimeric molecules were used, which may behave differently to the wild-type IL-33R␣-chain ligated with IL-33 (27) . We also detected transient JNK activation by IL-33 in a time frame comparable to the transient activation of this protein kinase by IL-1. In transiently transfected HEK293 cells, a slight shift in JNK activation was observed compared with IL-1 (1). In EL-4 cells, we could not see this effect, suggesting subtle differences in different cell types. Interestingly, although rhIL-1␤ was active in the picomolar range in EL-4 or transfected D6/76 cells, we required nanomolar concentrations of rmIL-33 (or rmIL-18) irrespective of the source of the rmIL-33 to achieve an effect. This result demonstrates the great potency of IL-1 when compared with its sister cytokines, IL-18 and IL-33.
Besides Th2 lymphocytes, mast cells are known to express high levels of IL-33R␣ (ST2) (28) . Therefore, we included murine BMD mast cells, which are nontransformed and nontransfected primary cells, in our studies. These cells responded readily to IL-33 by producing IL-6 like they did when TLR4 was activated by LPS. In addition, upon IL-33 stimulation, they produced TNF␣ and IL-1␤, two proinflammatory cytokines, whereas the 10 7 cells. In addition, some of the cells were cotransfected with 1 g of plasmid encoding C-terminally truncated mIL-1RAcP lacking the TIR domain (⌬C-AcP). One day later, transfectants were either stimulated with 10 ng/ml rhIL-1␤ or 100 ng/ml rmIL-33 for 15 min. IRAK-1 was immunoprecipitated from cell lysates by using mAb 2A9 (a kind gift from Z. Cao). Autophosphorylation of IRAK-1 was measured in an in vitro kinase assay and visualized by autoradiography. Transfection efficiency was on the order of 40% as ascertained by parallel transfections with EGFP plasmid and cytofluorometry. The data shown are of one representative experiment out of a series of three with comparable results. (B) Activation of the transcription factor NF-B by IL-33 depends on IL-1RAcP. D6/76 (Left) and EL-4 (Right) cells were transiently cotransfected with plasmids encoding mIL-33R␣-chain and an NF-B-dependent luciferase reporter plasmid (D6/76 cells, 0.5 g of plasmid each for 5 ϫ 10 6 cells; EL-4 cells, 0.5 g of reporter plasmid plus the indicated concentrations of plasmid for mIL-33R␣ or empty vector). In addition, in D6/76 cells, fl mIL-1RAcP was overexpressed. Cells were stimulated with either 100 ng/ml rmIL-33 (black bars) or 100 pg/ml rhIL-1␤ (gray bars) and either 100 ng/ml rmIL-18 or 100 ng/ml rhTNF␣, and luciferase activity was determined in the cell lysates the next day. Preincubation with 50 g/ml mAb 4C5 (white bars) was for 1 h before stimulation. constitutive production of IL-13 was not altered. We used mAb 4C5, which recognizes mIL-1RAcP (19, 20) and neutralizes IL-1␤-mediated signal transduction, to inhibit IL-33-mediated signaling in primary mast cells. 4C5 behaves similarly to the mAb M49, which neutralizes hIL-1RAcP and was used to inhibit IL-1RAcP-dependent signaling of IL-1F6 by IL-1Rrp2 in human cells (12) . We argued that if 4C5 recognizes mIL-1RAcP and functions by inhibiting the association of the coreceptor with the IL-1-ligated IL-1RI, it also should work in the IL-33 receptor system. We observed a concentration-dependent inhibition of IL-33 effects in the T cell lines EL-4 or D6/76 (after reconstitution with mIL-1RAcP) and, most important, also in mast cells.
At present, we do not know why 4C5 was less effective in inhibiting IL-33-stimulated responses when compared with IL-1␤. However, it has been described that this anti-IL-1RAcP antibody differs with respect to its neutralizing capacity between receptor complexes containing either IL-1␣ or IL-1␤ (19) . Thus, it is conceivable that this antibody also distinguishes between IL-1␤ in IL-1RI and IL-33 in IL-33R␣.
Summarizing the results achieved with anti-IL-1RAcP mAb in different systems (IL-1F6,-8,-9/IL-1Rrp2; IL-1/IL-1R; and IL-33/IL-33R) (12, 19, 20) , we must conclude that recognition of the receptor ␣-chain by IL-1RAcP is largely independent of the cytokine bound to the respective ␣-chain. A possible explanation may be that binding of ligand creates a conformational neoepitope on its respective receptor ␣-chain, which is structurally related such that it is recognized by IL-1RAcP. Presumably, the site in IL-1RAcP required for this recognition is affected by neutralizing anti-IL-1RAcP mAbs. No crystal structures of the ligated receptor-like members of the IL-1 receptor family with IL-1RAcP are available. However, a model was calculated in which two possible interactions of IL-1RAcP with IL-1-ligated IL-1RI were accommodated (29) . It was proposed that IL1RAcP could bind to IL-1-ligated IL-1RI by embracing IL-1 in the IL-1RI in a so-called FRONT model. In this model, residues of both ligand and receptor contribute to the association with IL-1RAcP. In light of the new results, which show a promiscuity of IL-1RAcP with respect to its ligated receptor ␣-chains, we favor the BACK model, in which IL-1RAcP recognizes the backbone of the ligated receptor that changes its conformation after IL-1 binding (30, 31) . In this model, the ligand contributes few or maybe no residues to the interaction.
In the EL-4 cell system, we investigated the requirement of the TIR domain for signal transduction initiated by IL-33 by overexpressing a C-terminally truncated version of IL-1RAcP lacking the TIR domain. IL-33 signaling was totally dependent on the presence of the TIR domain of the ␤-chain. We did not generate a C-terminally truncated version of the IL-33R␣-chain in this study to prove stringently that in fact both TIR domains are essential for IL-33 signaling. However, similar studies (12, 27) show that signaling is only possible when the TIR domain is present in ST2. Therefore, we must conclude that the TIR domains of the ␣-and ␤-chains are required for signal initiation.
We show here that the binding of IL-33 to the IL-33R␣ chain allows the formation of a complex with IL-1RAcP in the plasma membrane, as described for IL-1 binding to IL-1RI or IL-1RII (7) . In addition, we show that a soluble IL-33R␣-chain can interact with soluble IL-1RAcP in the presence of IL-33. The formation of (A) Membrane IL-33R␣-chain and IL-1RAcP form a complex in the presence of IL-33. HEK293RI cells were transiently transfected with plasmids encoding FLAG-tagged mIL-1RAcP and/or Myc-tagged mIL-33R␣. The next day, transfected cells were left unstimulated or stimulated with 10 ng/ml rhIL-1␤ or 100 ng/ml rmIL-33 for 15 min. Cells were lysed in the presence of 10 ng/ml rhIL-1␤ or 100 ng/ml rmIL-33, respectively. FLAG-tagged mIL-1RAcP was immunoprecipitated by using anti-FLAG M2 agarose beads. Precipitated proteins were visualized after SDS/PAGE by Western blot/ECL reaction with anti-Myc (Upper) and anti-FLAG (Lower) antibodies. The result shown is representative of five independent experiments with similar results. (B) Soluble forms of IL-33R␣-chain and IL-1RAcP form a complex in the presence of IL-33. srmIL-33R␣:Fc fusion protein was incubated in the absence or presence of rmIL-33 with FLAG-epitope-tagged srmIL-1RAcP fixed on FLAG-affinity gel. Coprecipitated fusion protein was visualized by Western blot after SDS/PAGE by using an anti-human IgG secondary antibody (see Materials and Methods).
soluble receptor complexes has been previously described in the IL-1 system (21), where soluble IL-1RAcP seems to stabilize the ligated soluble IL-1R, allowing neutralization and sequestration of the cytokine in vivo. It has been proposed that sIL-1RAcP may be helpful to neutralize IL-1␤ in chronic inflammatory diseases such as rheumatoid arthritis (21, 22) . It is tempting to speculate that sIL-1RAcP also could be used to neutralize and sequester IL-33 in the presence of sIL-33R␣-chain in Th-2-biased diseases (e.g., IgE-mediated allergic reactions).
In conclusion, our results demonstrate that the functional IL-33R complex consists of IL-33R␣ and IL-1RAcP. In addition, we show that the soluble forms of IL-33R␣ and IL-1RAcP can form complexes in the presence of IL-33. Thus, IL-1RAcP can act as a common ␤-chain for four discrete members of the IL-1 receptor family: IL-1RI, IL-RII, IL-1Rrp2, and IL-33R␣. This situation is reminiscent of the role of common receptor chains in other cytokine families, like gp130 in the IL-6 receptor system or the common ␥-chain in the IL-2 receptor family. In addition, the sharing of IL-1RAcP and the fact that it also can interact with receptors in its soluble form open new levels of cross-talking among the different members of the IL-1 receptor family.
Materials and Methods
Expression Plasmids. pFLAG-mIL33R␣ encodes amino acids 18 -567 of mIL-33R␣ with N-terminal 3ϫFLAG epitope tag under control of the CMV promoter in p3ϫFLAG-CMV-9 vector (Sigma-Aldrich). pMyc-mIL33R␣ encodes amino acids 18 -567 of mouse IL-33R␣ (without signal peptide) with N-terminal c-Myc epitope tag under control of the CMV promoter in pcDNA3.1/Zeo(ϩ) vector (Invitrogen), modified by insertion of mIL-2 signal sequence and c-Myc epitope sequence. pFLAG-mIL1RAcP encodes mIL-1RAcP with Nterminal FLAG epitope tag under control of the CMV promoter in pFLAG-CMV-1 vector (Sigma-Aldrich). ⌬C-mIL1RAcP (⌬C-AcP) encodes amino acids 1-384 of mIL-1RAcP (lacking the TIR domain) in pEF-Bos vector (generated by R. Hofmeister, University of Regensburg).
Others. The 3ϫNF-B-Luc reporter plasmid expresses firefly luciferase after binding of activated NF-B to three consecutive NF-B-binding sites in the promoter region of the plasmid.
Expression and Preparation of Purified Biotinylated IL-33 Protein.
Escherichia coli BL21 (DE3) cells were transformed with a bicistronic vector based on pETDuet (Novagen), which encodes the HA-tagged E. coli biotin ligase BirA and mature rmIL-33 comprising amino acids 109-266 (1) fused to an N-terminal minimal BirA substrate (GLNDIFEAQKIEWH) (32) . Biotin is added by BirA to the -amino group of lysine. Biotinylated rmIL-33 was affinity-purified by using UltraLink immobilized monomeric avidin (Pierce). IL-33 was eluted with 2 mM biotin in PBS containing protease inhibitors. The product was analyzed by using a protein 80 chip in a 2100 Bioanalyzer (Agilent) and shown to be essentially free of contaminants. Purified biotinylated rmIL-33 showed a biological activity comparable with commercially obtained material (Alexis).
Cytokines. rhIL-1␤ was a kind gift from D. Boraschi (Consiglio Nazionale delle Ricerche Institute for Biomedical Technology, Pisa, Italy). rmIL-33 was obtained from Alexis (ALX 522-101; Ͻ0.1 units LPS per g of protein). For stimulation of mast cells, only commercial IL-33 was used. For most experiments with EL-4, D6/76, or HEK293RI cells, biotinylated rmIL-33 produced in E. coli was used. Neither EL-4, D6/76, nor HEK293RI cells express TLR4 or respond to LPS, which might be present in minute amounts in our preparations despite extensive purification steps. rmIL-18 was obtained from Peprotech. rhTNF␣ was a kind gift from BASF Aktiengesellschaft (Ludwigshafen, Germany).
